{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-036179","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.736275+00:00","generated_at":"2026-06-09T00:52:11.894961+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Foghorn Therapeutics Q3 net loss narrows to $14.3M; cash runway into H1 2026","bullets":["Net loss $14.3M vs $25.8M YoY; collaboration revenue $17.5M incl. Merck termination.","Cash, equivalents, marketable securities $259.9M as of Sept 30; runway into H1 2026.","First patient dosed in FHD-286 combo study in AML; data expected H2 2024.","Transitioned BRM Selective inhibitor program to Loxo@Lilly under collaboration.","Preclinical data for EP300 and CBP selective degraders show tumor growth inhibition and no thrombocytopenia."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-036179","json":"https://secwatch.observer/filing/0001628280-23-036179.json","markdown":"https://secwatch.observer/filing/0001628280-23-036179.md","text":"https://secwatch.observer/filing/0001628280-23-036179.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023036179/0001628280-23-036179-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023036179/fhtx-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:52:11.894961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f6cb5a3b294d00e31e11e4c8c6377d3954ad3b03","claim":"Foghorn Therapeutics Inc. reported quarter ended September 30, 2023 results: revenue $17.5 million, net income $14.3 million.","evidence_excerpt":"$259.9 million in c ash, cash equivalents and marketable securities, which provides cash runway into the first half of 2026 . • Collaboration Revenues. Collaboration revenue was $17.5 million for the three months ended September 30, 2023, compared to $6.6 million for the three months ended September 30, 2022. The increase year-over-year was primarily driven by revenue","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023036179/0001628280-23-036179-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2023"},{"label":"Revenue","value":"$17.5 million"},{"label":"Net income","value":"$14.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}